Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phas...
1 transactions — including 0 buys declared by Amylyx Pharmaceuticals, Inc. executives to SEC / AMF / BaFin.
16 institutional funds report a position on AMLX in their latest SEC quarterly filing.
15 recent articles on AMLX.
Beyond raw data, we aggregate and score every smart money signal to give you a unique view.
8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.
Automatic detection when 3+ executives buy the same stock simultaneously — historically the most reliable signal.
Berkshire (Buffett), Pershing Square (Ackman), Tiger Global, Bridgewater + 200 more. Who buys what, each quarter.
NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.
Spot small caps whose retail interest explodes before the rest of the market. 100+ tickers monitored.
Create your watchlist and receive every morning at 8am the Brief of events on YOUR tickers.
This public page only shows a preview. The full analysis of AMLX on the Kairos Insider dashboard includes:
Free signup · Premium €29/month no commitment